Page 275 - Read Online

Lecchini et al. HCC vascular invasion in sorafenib treatment

F. Challenges of advanced hepatocellular carcinoma. World J real-life practice. Am J Clin Oncol 2017;40:167-74.
Gastroenterol 2016;22:7645-59. 22. Kudo M, Ueshima K, Arizumi T. Real life clinical practice with
11. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima sorafenib in advanced hepatocellular carcinoma: a single-centre
O, Kojiro M, Makuuchi M. Management of hepatocellular carcinoma experience. Dig Dis 2012;30:609-16.
in Japan: Consensus-Based Clinical Practice Guidelines proposed by 23. Trojniak MP, Palozzo AC, Mazurek M, Jirillo A. Sorafenib
the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis in hepatocellular carcinoma - a post marketing evaluation.
2011;29:339-64. Immunopharmacol Immunotoxicol 2012;34:419-22.
12. Poon D, Anderson BO, Chen LT, Tanaka K, Lau WY, Van 24. Chan SL, Chong CC, Chan AW, Poon DM, Chok KS. Management of
Cutsem E, Singh H, Chow WC, Ooi LL, Chow P, Khin MW Koo hepatocellular carcinoma with portal vein tumor thrombosis: review
WH. Management of hepatocellular carcinoma in Asia: consensus and update at 2016. World J Gastroenterol 2016;22:7289-300.
statement from the Asian Oncology Summit 2009. Lancet Oncol 25. Miyahara K, Nouso K, Morimoto Y, Takeuchi Y, Hagihara H, Kuwaki
2009;10:1111-8. K, Onishi H, Ikeda F, Miyake Y, Nakamura S, Shiraha H, Takaki
13. Bruix J, Sherman M. Management of hepatocellular carcinoma: an A, Iwadou S, Kobayashi Y, Takaguchi K, Takuma Y, Takabatake H,
update. Hepatology 2011;53:1020-2. Sakaguchi K, Yamamoto K; Okayama Liver Cancer Group. Efficacy
14. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, of sorafenib beyond first progression in patients with metastatic
Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, hepatocellular carcinoma. Hepatol Res 2014;44:296-301.
Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib 26. Nakano M, Tanaka M, Kuromatsu R, Nagamatsu H, Tajiri N, Satani
in patients in the Asia-Pacific region with advanced hepatocellular M, Niizeki T, Aino H, Okamura S, Iwamoto H, Shimose S, Shirono
carcinoma: a phase III randomised, double-blind, placebo-controlled T, Koga H, Torimura T; Kurume Liver Cancer Study Group of Japan.
trial. Lancet Oncol 2009;10:25-34. Sorafenib for the treatment of advanced hepatocellular carcinoma
15. Mendez-Sanchez N, Vasquez-Fernandez F, Zamora-Valdes D, Uribe with extrahepatic metastasis: a prospective multicenter cohort study.
M. Sorafenib, a systemic therapy for hepatocellular carcinoma. Ann Cancer Med 2015;4:1836-43.
Hepatol 2008;7:46-51. 27. Raoul JL, Adhoute X, Gilabert M, Edeline J. How to assess the
16. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H Chen efficacy or failure of targeted therapy: deciding when to stop sorafenib
C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, in hepatocellular carcinoma. World J Hepatol 2016;8:1541-6.
Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor 28. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de
I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta
PA. Sorafenib (BAY 43-9006, Nexavar) exhibits broad spectrum C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath
oral antitumor activity and targets the RAF/MEK/ERK pathway I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D,
and receptor tyrosine kinases involved in tumor progression and Bruix J; SHARP Investigators Study Group. Sorafenib in advanced
angiogenesis. Cancer Res 2004;64:7099-109. hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
17. Adnane L, Trail PA, Taylor I, Wilhelm SM. Sorafenib (BAY 43- 29. Iavarone M, Cabibbo G, Piscaglia F, Zavaglia C, Grieco A, Villa E,
9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK Cammà C, Colombo M; SOFIA (SOraFenib Italian Assessment) study
pathway in tumor cells and tyrosine kinases VEGFR/PDGFR tumor group. Field-practice study of sorafenib therapy for hepatocellular
vasculature. Methods Enzymol 2006;407:597-612. carcinoma: a prospective multicenter study in Italy. Hepatology
18. Liu L, Cao Y, Chen C, Zhang X, Mc Nabola A, Wilkie D, Wilhelm 2011;54:2055-63.
S, Lynch M, Carter C. Sorafenib blocks the RAF/MEK/ERK 30. D’Angelo S, Germano D, Zolfino T, Sansonno D, Giannitrapani
pathway, inhibits tumor angiogenesis, and induces tumor cell L, Benedetti A, Montesarchio V, Attili A, Buonadonna A, Barni S,
apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res Gasbarrini A, Burlone ME, Cillo U, Marenco S, Villa E, Giovanis
2006;66:11851-8. P, Proserpio I, Saitta C, Magini G, Cengarle R, Fava G, Cuttone F,
19. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch Calvani N, Angelico M, Di Costanzo F, Noto A, Poggi G, Marignani
M. Preclinical overview of sorafenib, a multikinase inhibitor that M, Cascinu S, Amoroso D, Palmieri V, Massa E, Crocè LS, Picardi A,
targets both Raf and VEGF and PDGF receptor tyrosine kinase Tumulo S, Erminero C, Lencioni R, Lorusso V. Therapeutic decisions
signaling. Mol Cancer Ther 2008;7:3129-40. and treatment with Sorafenib in hepatocellular carcinoma: final analysis
20. Di Marco V, De Vita F, Koskinas J, Semela D, Toniutto P, Verslype of GIDEON study in Italy. Recent Prog Med 2015;106:217-26.
C. Sorafenib: from literature to clinical practice. Ann Oncol 31. Kim DY, Kim HJ, Han KH, Han SY, Heo J, Woo HY, Um SH, Kim
2013;24:ii30-7. YH, Kweon YO, Lim HY, Yoon JH, Lee WS, Lee BS, Lee HC,
21. Choi GH, Han S, Shim JH, Ryu MH, Ryoo BY, Kang YK, Kim KM, Ryoo BY, Yoon SK. Real-life experience of sorafenib treatment for
Lim YS, Lee HC. Prognostic Scoring Models for patients undergoing hepatocellular carcinoma in Korea: from GIDEON data. Cancer Res
sorafenib treatment for advanced stage hepatocellular carcinoma in Treat 2016;48:1243-52.

Hepatoma Research ¦ Volume 3 ¦ November 16, 2017 267